Alkemists Pharmaceuticals – Trademark Portfolio
Entity Type: 03
Alkemists Pharmaceuticals owns a portfolio of 6 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), including well-known marks such as A, CRB, and COMPOSITE REFERENCE BOTANICAL. Of these, 3 are registered. The portfolio spans 3 Nice Classification classes, led by Class 1 (Chemicals) and Class 42 (Computer & Scientific). Headquartered in Garden Grove, CA.
12661 Hoover Street
Garden Grove, CA 92841
Showing of trademarks Trademarks
Trademark Classifications
Alkemists Pharmaceuticals's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Scientific and technological services; industrial analysis and research services
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Alkemists Pharmaceuticals have?
Alkemists Pharmaceuticals has 6 U.S. trademarks filed with the USPTO. Of these, 3 registered, 1 abandoned, 2 cancelled.
What trademark classes does Alkemists Pharmaceuticals file in?
Alkemists Pharmaceuticals files trademarks across 3 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 42 (Computer & Scientific), Class 5 (Pharmaceuticals). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.
What are Alkemists Pharmaceuticals's most well-known trademarks?
Alkemists Pharmaceuticals's registered trademark portfolio includes well-known marks such as A, CRB, and COMPOSITE REFERENCE BOTANICAL. These are among 3 currently registered trademarks in the portfolio.
What is Alkemists Pharmaceuticals's trademark registration success rate?
Alkemists Pharmaceuticals has a 50% trademark registration rate, with 3 out of 6 resolved applications resulting in successful registration. Currently, 0 applications are pending review.